Novo Nordisk signs licensing agreement with TTH  

2004.08.26
The Danish healthcare company has signed a licensing agreement with Canadian biotech company Transition Therapeutics (TTH)

Healthcare company Novo Nordisk has signed a licensing agreement with Canadian biotech company Transition Therapeutics (TTH) to develop TTH's Islet Neogenesis Therapy (INT) for the treatment of diabetes. The agreement also gives Novo Nordisk the opportunity to gain global rights to TTH's new technology. INT is a novel approach to regenerate insulin producing cells in the body, currently under development for the treatment of both Type I and Type II diabetes. The news is reported by financial newspaper Børsen online and on TTH's website.

 

Novo Nordisk is a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. Novo Nordisk employs 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London.

 

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×